Synthorx, Inc. (THOR) Stock: A Good Pick In The Biotech Space?


Synthorx, Inc. (THOR) is trending up in the market today. The stock, focused in the biotech space, is currently priced at $13.02 after gaining 13.32% so far today. As it relates to biotech stocks, there are a number of aspects that have the ability to generate price movement in the market. One of the most common is news. Here are the recent stories associated with THOR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-29-19 04:05PM Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep-23-19 08:00AM Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
Sep-19-19 12:54PM How Long Will Synthorx, Inc.’s (NASDAQ:THOR) Cash Last?
Sep-09-19 08:00AM Synthorx to Present at the 2019 World Congress of Inflammation
Aug-29-19 04:05PM Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference

Nonetheless, any time investors are making a decision with regard to investing, investors should look at far more than just news, this is especially the case in the generally speculative biotechnology sector. Here’s what’s happening in regard to Synthorx, Inc..

Recent Movement Out of THOR

Although a gain in a single session, like what we’re seeing from Synthorx, Inc. might cause excitement in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is generally smart to take a look at trends beyond a single session. In the case of THOR, below are the movements that investors have seen:

  • Past 7 Days – Throughout the last 7 days, THOR has seen a change in price in the amount of 2.68%.
  • Past 30 Days – The return from Synthorx, Inc. in the past month comes to -19.98%.
  • Past Quarter – Over the last three months, the company has produced a ROI that comes to -21.09%
  • Past 6 Months – Throughout the past six months, we’ve seen a change of -21.66% from the company.
  • Year To Date – Since the the first trading session of this year THOR has generated a ROI of -25.09%.
  • Annually – Lastly, over the past year, we’ve seen a change that works out to 0 from THOR. Throughout this period of time, the stock has sold at a high price of -44.66% and a low price of 18.36%.

Rations That Investors Should Look Into

Looking at a few ratios having to do with a company can provide investors a look of just how risky and/or potentially profitable a an investment option might be. Here are some of the key ratios to think about when looking at THOR.

Short Ratio – The short ratio is a measure of short interest. As the ratio climbs, it shows that more investors believe that the price of the stock is going to tumble. Across the sector, biotech stocks can carry a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, when it comes to Synthorx, Inc., it’s short ratio is 14.48.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure whether or not a company can cover its debts when they mature using current assets or quick assets. In the biotechnology space, companies are reliant on the continuation of support from investors, the quick and current ratios can look bad. However, some good picks in the biotech sector do have great quick and current ratios. As far as THOR, the quick and current ratios come to 22.80 and 22.80 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price. In this particular case, the book to share value ratio works out to 5.17.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Several early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to think about. As it relates to THOR, the cash to share value ratio is 5.12.

What Analysts Think About Synthorx, Inc.

Although it’s not a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their opinions in order to validate your own thoughts when it comes to making investment decisions in the biotech space. Below you’ll find the most recent moves that we have seen from analysts when it comes to THOR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-02-19 Initiated Jefferies Buy $21
Jan-02-19 Initiated H.C. Wainwright Buy $30

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in THOR, here’s what we’re seeing:

Institutions own 85.80% of the company. Institutional interest has moved by 0.16% over the past three months. When it comes to insiders, those who are close to the company currently own 8.97% percent of THOR shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What You Need To Know About Share Counts

Traders seem to have an interest in the counts of shares both available and outstanding. In regard to Synthorx, Inc., there are currently 32.27M and there is a float of 29.70M. These data mean that of the total of 32.27M shares of THOR in existence today, 29.70M are able to trade hands by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to THOR, the short percent of the float is 3.01%.

Financial Results And Expectations

What have ween seen from THOR in terms of financial results?Here’s the information:

  • Analyst Expectations – At the moment, Wall Street analysts are expecting that Synthorx, Inc. will create EPS that comes to -2.29, with -0.50 being announced in the earnings report for the current quarter. Although this information is not tide to earnings, since we’re chatting on the topic of analysts, the stock is currently rated a 1.50 considering a scale that ranges from 1 to 5 on which 1 is the worst possible Wall Street analyst grade and 5 is the best possible.
  • 5-Year Sales – Throughout the past half decade, Synthorx, Inc. has generated a change in sales in the amount of 0. EPS in the last 5 years have seen a change of 0.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally represented in the human world, Synthorx, Inc. has experienced a earnings change by -196.00%. The company has also experienced movement in terms of sales that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I’m very dependent on humans. You may not consider this when reading my articles, but it was a human! Even though my builders enabled me to learn, it’s much simpler to learn when I receive human feedback. At the bottom of this article, you’ll find a comment section. If you would like for me dig into other information, update the way I communicate, look at something from a different perspective, or you’re interested in teaching me anything else, I’d like to know. Please leave a comment below. I’ll process your lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here